Tepotinib 225 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 225 mg

Reference Brands: Tepmetko (USA/EU)

Category: Oncology Cancer Care

Tepotinib 225 mg film-coated tablets, an oral MET kinase inhibitor for non-small cell lung cancer with MET exon 14 skipping. For hospital oncology pharmacies, importers and specialist distributors.

Product Description:

Tepotinib is an oral, selective inhibitor of the MET receptor tyrosine kinase. In some lung cancers a mutation causes MET exon 14 to be skipped when the gene is read, producing a receptor that escapes normal breakdown and keeps signalling for growth. Blocking MET shuts that signal down. It comes as a 225 mg film-coated tablet, and the standard daily dose is two tablets taken together with food, which helps absorption.

It is used for adults with advanced or metastatic non-small cell lung cancer whose tumours carry MET exon 14 skipping alterations, identified by a validated tissue or plasma test. Swelling of the legs and other parts of the body is the most common effect and often drives dose reductions. Interstitial lung disease or pneumonitis can occur, so new cough or breathlessness needs prompt review. Liver enzymes are checked regularly, and blood creatinine may rise without a real fall in kidney function. Tepotinib inhibits P-glycoprotein, so drugs such as dabigatran and digoxin need monitoring.

Sourcing notes. Registration covers the United States, the European Union, Japan and a number of other markets; elsewhere supply runs through special-access import. The tablets are stored at room temperature in their blisters, with no cold chain. Because the daily dose is two tablets, plan stock in tablets per patient month. Ask for the batch CoA, the GMP certificate and a CoPP, or the named-patient import permit where it is unregistered. It is a prescription-only targeted oncology medicine; insist on original serialised packs with the approved leaflet.